ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion - Pharmaceutical Technology

Anktiva’s newfound FDA label expansion comes as the agency deems cases of CIS and high-grade papillary only NMIBC clinically similar. Anktiva’s newfound FDA label expansion comes as the agency deems cases of CIS and high-grade papillary only NMIBC clinically similar. Anktiva is the first therapy to be specifically approved by the FDA for the treatment of high-grade papillary only, BCG-unresponsive NMIBC. Credit: Antonio Marca / Shutterstock.com. The US Food and Drug Administration (FDA) has awarded a label expansion to ImmunityBio-owned Altor Bioscience’s bladder cancer therapy, Anktiva (nogapendekin alfa inbakicept-pmln), three months ahead of its original PDUFA date, making it the…

Source: Pharmaceutical Technology